UGT2B7

UGT2B7
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
Aliases UGT2B7, UDPGT 2B9, UDPGT2B7, UDPGTH2, UGT2B9, UDP glucuronosyltransferase family 2 member B7
External IDs MGI: 3576103 HomoloGene: 128251 GeneCards: UGT2B7
Genetically Related Diseases
obesity[1]
Orthologs
Species Human Mouse
Entrez

7364

231396

Ensembl

ENSG00000171234

ENSMUSG00000070704

UniProt

P16662

n/a

RefSeq (mRNA)

NM_001074

NM_001029867

RefSeq (protein)

NP_001065.2

n/a

Location (UCSC) Chr 4: 69.05 – 69.11 Mb Chr 5: 87.07 – 87.09 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

UGT2B7 (UDP-Glucuronosyltransferase-2B7) is a phase II metabolism isoenzyme found to be active in the liver, kidneys, epithelial cells of the lower gastrointestinal tract and also has been reported in the brain. In humans, UDP-Glucuronosyltransferase-2B7 is encoded by the UGT2B7 gene.[4][5]

Function

The UGTs serve a major role in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. UGT2B7 has unique specificity for 3,4-catechol estrogens and estriol, suggesting that it may play an important role in regulating the level and activity of these potent estrogen metabolites.

This enzyme is located on the endoplasmic reticulum and nuclear membranes of cells. Its function is to catalyse the conjugation of a wide variety of lipophilic aglycon substrates with glucuronic acid, using uridine diphosphate glucuronic acid.

Together with UGT2B4, UGT2B7 is capable of glucosidation of hyodesoxycholic acid in the liver, but, unlike the 2B4 isoform, 2B7 is also able to glucuronidate various steroid hormones (androsterone, epitestosterone) and fatty acids.[6][7] It is also able to conjugate major classes of drugs such as analgesics (morphine), carboxylic nonsteroidal anti-inflammatory drugs (ketoprofen), and anticarcinogens (all-trans retinoic acid).[7] UGT2B7 is the major enzyme isoform for the metabolism of morphine to the main metabolites, morphine-3-glucuronide (M3G) which has no analgesic effect and morphine-6-glucuronide (M6G),[8] which has analgesic effects less potent than morphine.[9] As a consequence, altered UGT2B7 activity can significantly affect both the effectiveness and side-effects of morphine, as well as some related opiate drugs.[10][11][12][13][14]

References

  1. ↑ "Diseases that are genetically associated with UGT2B7 view/edit references on wikidata".
  2. ↑ "Human PubMed Reference:".
  3. ↑ "Mouse PubMed Reference:".
  4. ↑ Ritter JK, Sheen YY, Owens IS (May 1990). "Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates". J. Biol. Chem. 265 (14): 7900–6. PMID 2159463.
  5. ↑ Monaghan G, Clarke DJ, Povey S, See CG, Boxer M, Burchell B (September 1994). "Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13". Genomics. 23 (2): 496–9. doi:10.1006/geno.1994.1531. PMID 7835904.
  6. ↑ Mackenzie P, Little JM, Radominska-Pandya A (February 2003). "Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7". Biochem. Pharmacol. 65 (3): 417–21. doi:10.1016/S0006-2952(02)01522-8. PMID 12527334.
  7. 1 2 Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, Ouzzine M (March 2007). "Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33". FEBS J. 274 (5): 1256–64. doi:10.1111/j.1742-4658.2007.05670.x. PMID 17263731.
  8. ↑ Coffman BL, Rios GR, King CD, Tephly TR (1 January 1997). "Human UGT2B7 catalyzes morphine glucuronidation". Drug Metab. Dispos. 25 (1): 1–4. PMID 9010622.
  9. ↑ van Dorp EL, Romberg R, Sarton E, Bovill JG, Dahan A (2006). "Morphine-6-glucuronide: morphine's successor for postoperative pain relief?". Anesthesia and Analgesia. 102 (6): 1789–1797. doi:10.1213/01.ane.0000217197.96784.c3. PMID 16717327.
  10. ↑ Coller JK, Christrup LL, Somogyi AA (2009). "Role of active metabolites in the use of opioids.". European journal of clinical pharmacology. 65 (2): 121–39. doi:10.1007/s00228-008-0570-y. PMID 18958460.
  11. ↑ Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y (2009). "Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer". Cancer chemotherapy and pharmacology. 65 (2): 251–8. doi:10.1007/s00280-009-1029-2. PMID 19466410.
  12. ↑ Abildskov K, Weldy P, Garland M (2010). "Molecular Cloning of the Baboon UDP-Glucuronosyltransferase 2B Gene Family and Their Activity in Conjugating Morphine". Drug metabolism and disposition: the biological fate of chemicals. 38 (4): 545–53. doi:10.1124/dmd.109.030635. PMC 2845934Freely accessible. PMID 20071451.
  13. ↑ Pergolizzi JV, Raffa RB, Gould E (2009). "Considerations on the use of oxymorphone in geriatric patients". Expert opinion on drug safety. 8 (5): 603–13. doi:10.1517/14740330903153854. PMID 19614559.
  14. ↑ Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P (2010). "Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes". Drug metabolism and disposition: the biological fate of chemicals. 38 (1): 40–5. doi:10.1124/dmd.109.029546. PMID 19841060.

Further reading

This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.